The blood test that goes looking for tangles, not plaques
A plasma marker called eMTBR-tau243 tracks Alzheimer's tau tangles rather than amyloid. Three published cohorts say it works as a measure. None of them says yet who should be treated.
The latest sourced reporting on Progressive Supranuclear Palsy from Dementias Today: dated, and plain about what the evidence does and does not show.
A plasma marker called eMTBR-tau243 tracks Alzheimer's tau tangles rather than amyloid. Three published cohorts say it works as a measure. None of them says yet who should be treated.
A new preprint from a Berkeley structural biology lab used cryo-electron tomography on cultured neurons and astrocytes and found no evidence that tau fibrils tear their way out of lysosomes. The compartments stayed intact. The leak, the authors argue, is something subtler. This is laboratory cell work, not peer reviewed, and not a treatment.
A Neuron paper from Stanford and UCSF describes a route from tau to neuron death that never passes through a tangle. It is fly, mouse, stem cell and post-mortem work, and the compound that blocks it has not been given to a single person.
A data-driven cascade model in 489 patients with bvFTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome and FTD-ALS places plasma GFAP first and steep clinical decline last. The work is observational and its authors present it as a framework for staging and trial design, not as a test for any individual.
Erasmus MC sequenced the temporal cortex of 18 people with FTLD-TDP type C, the pathology that almost always underlies semantic variant PPA, and found postsynaptic gene activity reduced after adjusting for tissue and disease overlap. The work is descriptive, not causal.
[11C]MODAG-005 lit up the brains of three patients in Tuebingen, and the peer-reviewed evidence is strongest exactly where synuclein packs tightest: multiple system atrophy. Whether it can see the sparser deposits of dementia with Lewy bodies is still unsettled.
A Japanese tau-PET study of 37 people with progressive supranuclear palsy reports that executive difficulty follows the connections leading out of the tau, not the amount of tau itself. The study is cross-sectional and cannot show that removing tau would change cognition.
A model trained on autopsy-confirmed brains was used to pick participants for imaginary trials in progressive supranuclear palsy and corticobasal degeneration. On paper, the numbers needed fell by half for PSP and by 87 percent for CBD. The trials are still imaginary.
The Progressive Supranuclear Palsy Clinical Trial Platform, run under one master protocol at 50 US sites, has taken in its first participant. Two regimens are registered: Axon Neuroscience's AADvac1 and PharmatrophiX's LM11A-31. No results exist yet.